LINGO-1 is a New Therapy Target and Biomarker for Ewing Sarcoma.
MetadataShow full item record
Ewing sarcoma is a predominantly paediatric cancer with a high rate of metastasis and reoccurrence. A new surface marker called LINGO-1 was recently identified on Ewing tumours as a potential target for antibody-mediated therapies. However, such targeting requires caution because of LINGO-1 expression on some brain cells. Although the blood-brain-barrier exists, small amounts of antibody may cross this barrier and cause harmful side-effects. In this perspective, we suggest some options to alleviate this risk that can make targeting tumour cells expressing the LINGO-1 antigen a safe option.
Chromosomal Translocations and Intracellular Antibody Therapeutics
License start date
Clinics in oncology (Belmont, Calif.), 2017, 2 pp. 1183 - ?